The Cancellation Price is 50% lower than Henlius's IPO price, causing losses for long-term players. Remaining public will provide good returns. There would be investors vote against the privatization
What is covered in the Full Insight:
Introduction and Overview
Details of the Cancellation Price
Performance and Growth Potential of Henlius
Market Reaction and Shareholder Sentiment
Fosun Pharma's Financial Situation and Risks
SUMMARY
(Sign Up to Access)
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
Unlock all research summaries
Follow top, independent analysts
Receive personalised alerts and emails
Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.